ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO071

Pannexin1 Regulates Intracellular ATP in a Cisplatin Model of AKI

Session Information

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms


  • Jankowski, Jakub, University of Virginia, Charlottesville, Virginia, United States
  • Yao, Junlan, University of Virginia, Charlottesville, Virginia, United States
  • Zheng, Shuqiu, University of Virginia, Charlottesville, Virginia, United States
  • Bajwa, Amandeep, University of Virginia, Charlottesville, Virginia, United States
  • Rosin, Diane L., University of Virginia, Charlottesville, Virginia, United States
  • Isakson, Brant, University of Virginia School of Medicine, Charlottesville, Virginia, United States
  • Ravichandran, Kodi S., University of Virginia, Carter Immunology Center, Charlottesville, Virginia, United States
  • Okusa, Mark D., University of Virginia, Charlottesville, Virginia, United States

Pannexin1 (Panx1) is a membrane channel that can release ATP upon injury, thereby exacerbating inflammation. We reported that Panx1 deficiency protects kidneys from ischemia-reperfusion injury (IRI). We found significant differences in kidney ATP between Panx1 KO and control kidneys after injury and hypothesized that retention of ATP is a universal protective mechanism in AKI, including the cisplatin model.


Global Panx1 KO and WT mice (n=4) were subjected to 26min bilateral kidney ischemia and 24h of reperfusion. Global (n=8) and proximal tubule (PT, n=4) Panx1 KO mice and appropriate controls (n=6 and 4, respectively) were given cisplatin (20 mg/kg, ip). Injury was assessed 72 h later by plasma creatinine (PCr), blood urea nitrogen (BUN) and weight loss. Whole kidney ATP was obtained by chloroform extraction of kidney homogenates. CRISPR/Cas9 was used to generate stable Panx1 KO in murine proximal tubule cells (TKPTS). Cells were treated with 20 µM cisplatin overnight or 20 µM antimycin A for 1 hour to induce injury. Intracellular ATP concentration was measured using luminescent assay.


At baseline, global Panx1 KO had less ATP (normalized to tissue weight) in whole kidney homogenates than WT mice (n=8 and 9; 0.59 vs. 1.00; p<0.05). Following IRI kidney ATP was higher (2.9 vs. 1.0; p<0.05) and PCr was lower (0.48 vs. 1.45 mg/dL; p<0.01) in Panx1 KO than in WT mice. After cisplatin, BUN was higher in Panx1 KO than WT mice (81.74 vs. 58.46 mg/dL; p=0.07) but there was no difference in kidney ATP (0.89 vs. 0.92; p=0.879). Similarly, after cisplatin, BUN (113.8 vs. 61.49 mg/dL; p<0.05) and body weight loss (21.76 vs. 17.37%; p<0.05) was higher in PT-specific Panx1 KO than WT mice. Kidney ATP was not greater in PT-Panx1 KO than WT mice (1.31 vs. 1.00; p=0.34) after cisplatin treatment. Cultured Panx1 KO cells retained more ATP than controls after cisplatin (54 vs. 36%, p<0.0001) or antimycin A (66 vs. 49%, p<0.001) treatment.


These results show that Panx1 influences ATP balance in cisplatin injury setting. PT-specific Panx1 deletion is sufficient to exacerbate injury, contrary to in vitro observations that Panx1 knockout tubules retain more ATP after antimycin A or cisplatin stimulation. The complex role of intracellular ATP homeostasis in AKI will require additional investigation.


  • NIDDK Support